Filing Flows › Interpace Biosciences (IDXG) › Q1 2026 › vs Q4 2025
Interpace Biosciences (IDXG) Q1 2026 vs Q4 2025 (quarter over quarter)
Interpace Biosciences's revenue fell $192K (-2%) from $9.2M in Q4 2025 to $9.0M in Q1 2026. Gross margin 65.4% against 65.5% (-0.2 pts).
Interpace Biosciences, Q1 2026: revenue $9.0M (-22% year over year), operating margin 12.4%, net earnings $721K, operating cash flow $283K. The chart draws each line against Q4 2025, the increases inside each band.
Margins
| Q1 2026 | Q4 2025 | Change | |
|---|---|---|---|
| Gross margin | 65.4% | 65.5% | -0.2 pts |
| Operating margin | 12.4% | 17.1% | -4.7 pts |
| Net margin | 8.0% | 245.6% | -237.6 pts |
| Free cash flow margin | 1.6% | 22.8% | -21.2 pts |
Every line
| Line | Q1 2026 | Q4 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $9.0M | $9.2M | −$192K | -2% |
| Gross profit | $5.9M | $6.0M | −$140K | -2% |
| Cost of revenue | $3.1M | $3.2M | −$52K | -2% |
| Operating profit | $1.1M | $1.6M | −$454K | -29% |
| Operating expenses | $4.8M | $4.5M | $314K | +7% |
| Pre-tax earnings | $1.0M | $1.4M | −$417K | -29% |
| Other expense, net | $100K | $137K | −$37K | -27% |
| Research & development | $153K | $142K | $11K | +8% |
| Sales & marketing | $2.2M | $2.1M | $64K | +3% |
| General & admin | $2.5M | $2.2M | $239K | +11% |
| Net earnings | $721K | $22.7M | −$21.9M | -97% |
| Income tax | $302K | −$21.2M | $21.5M | — |
| Depreciation & amortization | $118K | $118K | $0 | 0% |
| Share-based compensation | $4K | $4K | $0 | 0% |
| Working capital & other | $560K | $20.6M | −$20.1M | -97% |
| Operating cash flow | $283K | $2.1M | −$1.9M | -87% |
| Free cash flow (OCF − capex) | $142K | $2.1M | −$2.0M | -93% |
| Capital expenditures | $141K | $38K | $103K | +271% |
Questions
How much did Interpace Biosciences's revenue grow quarter over quarter in Q1 2026?
Interpace Biosciences's revenue fell $192K (-2%) from $9.2M in Q4 2025 to $9.0M in Q1 2026. Gross margin 65.4% against 65.5% (-0.2 pts).